May, 2026 Clinical Studies in Aging

#1

Everolimus Aging Study (NCT05835999)

  • What’s being done: low-dose everolimus to test whether mTORC1 inhibition can improve physiological and molecular hallmarks of aging.
  • Population: older adults with metabolic-risk enrichment.
  • Phase / status: Phase 2, ongoing.
  • Expected next milestone: no clear public timing confirmed in this pass.
  • Why it matters: one of the clearest human studies directly testing mTOR inhibition as a geroscience intervention.
  • Main caveat: public milestone timing was not cleanly retrievable in this pass.
  • Source: https://clinicaltrials.gov/study/NCT05835999

Rapalog Pharmacology (RAP PAC) Study (NCT05949658)

  • What’s being done: weekly sirolimus and everolimus dose-finding to identify safer rapalog dosing strategies for aging intervention.
  • Population: adults in an aging-focused pharmacology study.
  • Phase / status: early-phase dose-finding study, ongoing.
  • Expected next milestone: no clear public timing confirmed in this pass.
  • Why it matters: likely to shape dosing strategy for future rapalog trials in geroscience.
  • Main caveat: more methodological than efficacy-oriented.
  • Source: https://clinicaltrials.gov/study/NCT05949658

The Role of Sirolimus in Preventing Functional Decline in Older Adults (NCT05237687)

  • What’s being done: sirolimus trial aimed at aging biomarkers and functional decline in older adults.
  • Population: older adults.
  • Phase / status: interventional study, ongoing.
  • Expected next milestone: no clear public timing confirmed in this pass.
  • Why it matters: one of the clearer efforts to connect rapalog treatment to functional aging outcomes.
  • Main caveat: milestone timing needs direct registry confirmation before any dated forecast.
  • Source: https://clinicaltrials.gov/study/NCT05237687

ER-100 in Optic Neuropathies (NCT07290244)

  • What’s being done: first-in-human safety/tolerability study of a single dose of ER-100 in optic nerve disorders.
  • Population: adults with glaucoma or non-arteritic anterior ischemic optic neuropathy.
  • Phase / status: Phase 1, safety-focused.
  • Expected next milestone: early safety/tolerability information; no clear public date confirmed in this pass.
  • Why it matters: one of the most visible clinical entries adjacent to regenerative or reprogramming-based aging biology.
  • Main caveat: disease-specific and very early phase.
  • Source: https://clinicaltrials.gov/study/NCT07290244

Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women (NCT07057310)

  • What’s being done: GLP-1 agonist trial testing whether weight-loss treatment improves physical and vascular aging-related outcomes.
  • Population: postmenopausal women with obesity.
  • Phase / status: interventional study, ongoing.
  • Expected next milestone: no clear public timing confirmed in this pass.
  • Why it matters: GLP-1 therapy is increasingly relevant where function and vascular health are measured directly rather than weight alone.
  • Main caveat: aging relevance may be partly mediated through obesity improvement rather than a direct gerotherapeutic mechanism.
  • Source: https://clinicaltrials.gov/study/NCT07057310
#2

I’ve looked at the timeframe for this study, and I don’t see any follow-up outcomes measures past 24 weeks, which is exactly when the study ends. Is that correct? Seems short-sighted. Most of the robust studies I can think of had a follow-up period, which is where the effects/benefits of prior mtor inhibition really showed.

#3

The innovation here is not in the patient population, since you could find this exact population in the dozen or so GLP1 trials that have previously run. The various physical functions measured make it a little more interesting.